This study was approved by the Ethics Committee of the Third People’s Hospital of Shenzhen, China, on January 23, 2020. Informed consent was obtained from the patients’ guardians.
Clinical and epidemic findings: We obtained clinical data and possible exposures to 2019-nCoV by direct interviewing with their guardians. All symptoms, physical examination, laboratory, and image data were obtained from medical records. The patients’ inclusion criteria were: (1) below 18 years old, (2) laboratory-confirmed 2019-nCoV infection with PCR (polymerase chain reaction) test of the virus in samples taken from the respiratory tract of the patient, and (3) patients admitted to the Third People’s Hospital of Shenzhen from January 11, 2020 to February 11, 2020. The exclusion criteria were suspected cases of 2019-nCoV without a confirmed diagnosis. All acquired data were crosschecked by two physicians to ensure that there was no duplicated data. Clinical classification was recommended according to the diagnostic criteria.
Specimen collection: Nasopharyngeal swabs, sputum, blood and/or tracheal aspiration samples were tested for nucleic acid from each patient at various times. Two sets of nasopharyngeal swab samples were collected at initial diagnosis. Follow-up sets of specimens were collected after symptoms had disappeared.
2019-nCoV laboratory testing: Specimens were tested using a 2019-nCoV real-time reverse transcription PCR (RT-qPCR) method. A licensed kit was recommended by National microbiology Data Center of China for detection of 2019-nCoV. The related laboratory information shows below.
Target 1 (ORF1ab):
Ct value of virus>40 is negative, <37 is positive, between 37 and 40 is susceptive and timely continuous testing is recommended. All PCR procedures were done at Center for Disease Control and Prevention of Shenzhen and the results were reported within 48 hours of collection.
Treatment: According to the guideline, Lopinavir/litonavir (200mg/50mg), the recommended doses: weight 7-15kg, 12mg/3mg/kg; weight 15-40 kg, 10 mg/2.5 mg/kg; weight >40 kg, 400 mg/100 mg as adult each time, twice a day for 1-2 weeks. Interferon-α2b nebulization, 100,000-200,000 IU/kg, twice a day for 5-7 days. No patients received intravenous immunoglobulin (IVIG) and methyl-prednisone.
Data analysis: Basic descriptive analyses were carried out in all patients. A result of p value<0.05 indicated statistically significant. IBM SPSS statistics was used for statistical analyses.